Oct 24, 2026
Exciting Milestones for the UPMC Enterprises Portfolio
This October, we proudly announced three updates from the UPMC Enterprises portfolio from Cerevance, VeloSource, and Estuary Biotherapeutics. Together, these milestones demonstrate how UPMC Enterprises works alongside company leaders and experts across UPMC to advance promising solutions to significant health care challenges.
On Oct. 7, Cerevance announced positive Phase III results for solengepras, a once-daily adjunctive treatment for Parkinson’s disease. The results position the drug for potential regulatory approval and represent an important milestone after six years of partnership. Thank you to Matthias Kleinz for his leadership and support of Cerevance throughout this journey.
On Oct. 14, UPMC Enterprises to announce a strategic investment in VeloSource, a health care workforce solutions provider powered by the Syncx platform. The investment will help advance technology designed to address physician staffing challenges, strengthen workforce management and support access to care.
As part of the partnership, Richard Wadas, MD, will assume the title of chief medical officer at VeloSource while maintaining his positions at UPMC. Congratulations to the colleagues across UPMC Enterprises and UPMC who made this investment possible, and for the continuous dedication to improving care delivery.
Thank you to Nick Shapiro, Craig Ball, Curtis Stratman, Maryam Jalal, and Kritika Verma, along with our Legal, Finance, and Marketing/PR teams, for advancing this partnership.
On Oct. 16, Estuary Biotherapeutics also joined the UPMC Enterprises portfolio. The company is developing kidney-targeted gene therapies designed to address the underlying genetic cause of ADPKD, with the potential to move beyond slowing progression toward meaningfully changing the course of the disease.
The investment reflects UPMC Enterprises’ focus on supporting promising innovations that address significant health care challenges and have the potential to improve patient outcomes. Thank you to Ketki Karanam, Rosheema Bala, Julian Hassinger, and Fabian Tenenbaum for their diligence on this investment, as well as our Legal, Finance, and Marketing/PR teams for their support.
